

ASX ANNOUNCEMENT

19 March 2026

Termination of proposed sale and leaseback transaction

Little Green Pharma Ltd (ASX:LGP) ("**LGP**" or the "**Company**") refers to its announcement dated 19 February 2026 announcing it had signed a Contract to sell and lease back its production facility in South-West Western Australia subject to various conditions precedent.

Further to that announcement, the Company confirms the Parties were unable to reach commercial agreement in relation to certain matters the subject of conditions precedent in the Contract, meaning the Contract has now terminated in accordance with its terms. This means the proposed sale and leaseback will not proceed and LGP will continue to own the production facility. Termination of the proposed sale and leaseback is not expected to impact LGP's business or operations.

ENDS
BY ORDER OF THE BOARD

A stylized, handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
E: cosec@lgp.global
T: +61 8 6280 0050

Paul Long
Managing Director

Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>

Access past Cannabis Wraps here: <https://www.investlittlegreenpharma.com/site/investor-centre/cannabis-industry-wrap>